Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links

Drugs

-

Gonadotropin-Releasing Hormone (GnRH) Agonists Information

Gonadatripon-Releasing Hormone (GnRH) Agonists are medications used in the treatment of prostate cancer.

To report any serious adverse events associated with the use of these drugs, please contact the FDA MedWatch program using the contact information at the bottom of this page.

-

Safety Information

FDA Drug Safety Communication: Update to Ongoing Safety Review of GnRH Agonists and Notification to Manufacturers of GnRH Agonists to Add New Safety Information to Labeling Regarding Increased Risk of Diabetes and Certain Cardiovascular Diseases
10/20/2010
FDA Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certain cardiovascular diseases
5/3/2010
FDA Conducting Safety Review of Commonly Used Prostate Cancer Drugs
FDA press release (5/3/2010)
Podcast for Healthcare Professionals: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certain cardiovascular diseases
5/6/2010

-

Contact FDA

1-800-332-1088

1-800-FDA-0178 Fax

Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857

-

-